Tag: Dr Jayanth Sridhar
Coya Therapeutics partners with Dr. Reddy’s for neurodegenerative disease therapy development
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking ... Read More
FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a ... Read More
Dr. Reddy’s Tocilizumab biosimilar shows promising results in phase 1 trial
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a ... Read More